Twitter | Search | |
Search Refresh
Michael Fitzmaurice Dec 15
Excellent performance against a good team. Gundogan and Jesus were impressive. Laporte imperious.
Reply Retweet Like
TJ Kelley Jul 15
25th Annual Motor City Roundball Classic at Ferndale HS, Dec 27-30, 2019! loaded event with many of the the Midwest's best teams!
Reply Retweet Like
Array BioPharma Jun 14
: Check out our topline results in .
Reply Retweet Like
A.n.n. Aug 14
Really good point re need for HER2 testing right away (for EGFR treatment info & for clinical trial option in 2nd line) for pts REALLY good video. Good discussion at end re reimbursement of panel testing - especially if there has already been an NGS panel done.
Reply Retweet Like
Cure GI Cancers Jan 14
In recent years, researchers have identified several mutations in patients with that can help with prognostication and guide treatment decision making, which makes these tests essential to optimizing care. via
Reply Retweet Like
Predepression Jun 20
Reply Retweet Like
Jun Gong Jun 3
Phase II CO.26 update durva+treme vs BSC positive OS benefit in refractory- MSS for TMB>28 (note 42% had TMB >20). nivo-ipi+RT to met sites in MSS w/durable responses but high toxicity. Immunoscore in stage III crc identifies at high risk of relapse/death
Reply Retweet Like
Iga Rawicka Jan 30
I would like to compare how much pharma companies invested in research in Poland and how much Polish government spent on new gastric drugs developement for last 25 years. By the way we still miss III & IV line in for Polish patients
Reply Retweet Like
Rebecca Cherniak Jan 23
Replying to @MichaelChaikof
Oh how I miss my favourite Caesarean partner!
Reply Retweet Like
Umberto Malapelle Apr 14
Proud to be part of this excellent group @matteofassan Class 1, 2 and 3 BRAF mutated metastatic colorectal cancer: a detailed clinical, pathological and molecular characterization
Reply Retweet Like
Array BioPharma Jul 22
: The BRAF mutation is present in up to 15% of all patients with ?
Reply Retweet Like
ReachMD May 22
What clinical factors should you consider when sequencing treatment for your patients?
Reply Retweet Like
Andrew Beattie May 11
Another year of pkf_newcastle ‘behind’ the greens!! @ Merewether
Reply Retweet Like
Earl Ray Martin Apr 14
After a run, I’m starving. Today, it seems I’m having Oven Roasted Chick Peas and Purple Cabbage. WHY having I not done this before?
Reply Retweet Like
SanDiegoMesaCollege May 10
Thank you to everyone who was a part of . Everyone did a great job👏! Much appreciation 💛💙 to our faculty mentors, judges and committee who make this annual event such a huge success!
Reply Retweet Like
Array BioPharma Jun 6
: It is recommended that all patients with metastatic be tested for a BRAF mutation, regardless of tumor sidedness?
Reply Retweet Like
Inna Kanevsky May 8
When you’ve been working on conference posters for so long, even the professor is loopy. MCRC, here they come!
Reply Retweet Like
Roxanne Kearns Dill Mar 13
Replying to @KYOVERALL
See our accounting tutor ASAP!
Reply Retweet Like
Caroline Hopkins Jan 10
"What if we demanded more medical researchers and doctors and nurses and nutritionists on the streets to keep us safe? What if we demanded more hospital beds like we demand more prison beds?" powerful essay by
Reply Retweet Like
Alessio Cogoni Apr 6
Replying to @mtmdphd @JAMAOnc
Absolutely agree with this point of view on the actual value of testing in : not ready yet to use it for excluding patients candidate to antiEGFR therapy
Reply Retweet Like